Travere Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 89 to 92.
Here Are 3 Keys For Successful Stock Investing
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an 80 or higher RS Rating at the beginning of a new price run.
The IBD 50 stock is now considered extended and out of buy range after clearing a 19.08 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% earnings growth last quarter. Sales gains came in at 111%.
Travere Therapeutics earns the No. 13 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
